Presidio Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Presidio Pharmaceuticals Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013970
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Presidio Pharmaceuticals Inc (Presidio) is a clinical-stage pharmaceutical company that discovers and develops small-molecule antiviral therapeutics. The company’s products include HCV NS5A, NS5B proteins, lead pan-genotypic HCV NS5A inhibitor, ravidasvir hydrochloride, protease inhibitor, faldaprevir and non-nucleoside inhibitor. Presidio’s lead pan-genotypic HCV NS5A inhibitor, ravidasvir hydrochloride has completed phase 1 clinical studies in both healthy volunteers and HCV patients. Its second pan-genotypic HCV inhibitor PPI-383 is a NS5B non-nucleoside inhibitor currently being evaluated in phase 1 studies. The company also has an extensive intellectual property portfolio for its HCV programs. Presidio is headquartered in San Francisco, California, the US.

Presidio Pharmaceuticals Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Presidio Pharma Raises Additional USD13 Million in Series D Venture Financing 10
Presidio Pharma Raises US$8.6 Million In Series D Financing 11
Presidio Pharma Raises Additional US$8 Million In Series C Financing 12
Presidio Pharma Secures US$3 Million In Venture Financing 13
Licensing Agreements 14
Pharco Pharma Enters into Licensing Agreement with Presidio Pharma for PPI-668 14
Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 15
Presidio Pharmaceuticals Inc – Key Competitors 16
Presidio Pharmaceuticals Inc – Key Employees 17
Presidio Pharmaceuticals Inc – Locations And Subsidiaries 18
Head Office 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts 2
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Presidio Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Presidio Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Presidio Pharma Raises Additional USD13 Million in Series D Venture Financing 10
Presidio Pharma Raises US$8.6 Million In Series D Financing 11
Presidio Pharma Raises Additional US$8 Million In Series C Financing 12
Presidio Pharma Secures US$3 Million In Venture Financing 13
Pharco Pharma Enters into Licensing Agreement with Presidio Pharma for PPI-668 14
Ascletis Enters into Licensing Agreement with Presidio Pharma for PPI-668 15
Presidio Pharmaceuticals Inc, Key Competitors 16
Presidio Pharmaceuticals Inc, Key Employees 17

★海外企業調査レポート[Presidio Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • TriVascular Inc:医療機器:M&Aディール及び事業提携情報
    Summary TriVascular Inc (TriVascular), a subsidiary of Endologix Inc is a medical device company that researches, designs and manufactures technologies to provide optimal solutions for endovascular aortic repair. The company’s product comprise endovascular grafts and self-expanding stent grafts; ova …
  • Vivus Inc (VVUS):企業の財務・戦略的SWOT分析
    Vivus Inc (VVUS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Dartmouth College-製薬・医療分野:企業M&A・提携分析
    Summary Dartmouth College (Dartmouth) is an academic and research institute that offers undergraduate and graduate educational programs. The institute offers programs in the fields of arts, sciences, business administration, medicine, and engineering. It operates through various faculties such as th …
  • Nihon Kohden Corporation:戦略・SWOT・企業財務分析
    Nihon Kohden Corporation - Strategy, SWOT and Corporate Finance Report Summary Nihon Kohden Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • SBS Transit Ltd.:戦略・SWOT・企業財務分析
    SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report Summary SBS Transit Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Natco Pharma Ltd (NATCOPHARM):製薬・医療:M&Aディール及び事業提携情報
    Summary Natco Pharma Ltd (Natco Pharma) focuses on the research, development, manufacture and commercialization of pharmaceutical substances and finished dosage forms. The company offers finished dosage forms in capsule, injection and tablet. Its products are indicated to treat multiple sclerosis, i …
  • Diversicare Healthcare Services Inc (DVCR):企業の財務・戦略的SWOT分析
    Summary Diversicare Healthcare Services Inc (Diversicare), formerly Advocat Inc is a healthcare service provider that offers post acute care services and short term rehabilitation and long-term care services to nursing home patients. The company offers services such as life steps rehabilitation prog …
  • My Health Direct Inc:医療機器:M&Aディール及び事業提携情報
    Summary My Health Direct Inc (MHD) is a healthcare technology company that offers web-based solutions for the management of healthcare appointments. The company helps clients in achieving incremental revenue growth and real-time cost containment savings. It offers products such as consumer direct an …
  • Australian Leaders Fund Limited
    Australian Leaders Fund Limited - Strategy, SWOT and Corporate Finance Report Summary Australian Leaders Fund Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Tata Motors Ltd (TATAMOTORS):企業の財務・戦略的SWOT分析
    Tata Motors Ltd (TATAMOTORS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Downer EDI Ltd (DOW)-石油・ガス分野:企業M&A・提携分析
    Summary Downer EDI Limited (Downer) is a diversified services company. The company offers wide range of services such as transport infrastructure, engineering, utility, construction, and maintenance., It also provides mining services such as open-cut mining, crushing, underground mining operations, …
  • Enterome Bioscience SA:医療機器:M&Aディール及び事業提携情報
    Summary Enterome Bioscience SA (Enterome) is a drug development company which develops medical tests, and companion diagnostics to develop the management of microbiome-related diseases. The company develops medical tests based on its metagenotype technology platform that helps to identify microbiome …
  • De’Longhi S.p.A. (DLG):企業の財務・戦略的SWOT分析
    De'Longhi S.p.A. (DLG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Sunshine Biopharma Inc (SBFM):企業の財務・戦略的SWOT分析
    Summary Sunshine BioPharma Inc (Sunshine BioPharma), a subsidiary of Advanomics Corp is a pharmaceutical company that offers research, development and commercialization of drugs for treating cancer disease. The company provides generic and proprietary drugs for the treatment of cancer and other acut …
  • Nine Entertainment Co. Holdings Ltd:企業の戦略・SWOT・財務分析
    Nine Entertainment Co. Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Nine Entertainment Co. Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • SANUWAVE Health Inc (SNWV):医療機器:M&Aディール及び事業提携情報
    Summary Sanuwave Health Inc (Sanuwave), formerly Rub Music Enterprises Inc, is a medical device company that develops and commercializes noninvasive biological response activating devices. The company offers products such as dermapace, which is used in the treatment of chronic and acute conditions o …
  • Carlsberg Brewery Malaysia Berhad:戦略・SWOT・企業財務分析
    Carlsberg Brewery Malaysia Berhad - Strategy, SWOT and Corporate Finance Report Summary Carlsberg Brewery Malaysia Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Kadmon Corp LLC-製薬・医療分野:企業M&A・提携分析
    Summary Kadmon Corp LLC (Kadmon) is a biopharmaceutical company that offers products and related services for the management and treatment of hepatitis C. The company also develops therapies for metabolic and serious diseases. Its products include ribavirin, USP Tablets, ribavirin capsules, phenterm …
  • Neurim Pharmaceuticals Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Neurim Pharmaceuticals Ltd (Neurim) is a drug discovery company that develops drugs for central nervous system diseases.The company's product line includes circadin that is used in insomnia treatment. Neurim offers paediatric prolonged-release melatonin, piromelatine, NEU-P12 and NEU-240. Th …
  • Uzma Bhd (UZMA):企業の財務・戦略的SWOT分析
    Summary Uzma Bhd (Uzma) is an oil and gas service and equipment company. The company provides integrated solutions to the upstream sector. It offers geoscience and petroleum engineering, laboratory solutions, drilling and well services, production operation and optimization, manpower consultancy and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆